A phase 2 study has been initiated with the Mayo Clinic in which patients have been preselected for mTOR pathway activations. The study is a ‘basket’ trial that will study combination therapies in patients with renal cell carcinoma, head and neck cancer, Bladder cancer, Endometrial cancer, Breast cancer, Ovarian cancer, Prostate cancer, and Squamous cervical/uterine cancer.